Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease

INTRODUCTION: Afatinib is an effective first-line treatment in patients with epidermal growth factor receptor (EGFR)-mutated non–small-cell lung cancer (NSCLC) and has shown activity in patients progressing on EGFR-tyrosine kinase inhibitors (TKIs). First-line afatinib is also effective in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoffknecht, Petra, Tufman, Amanda, Wehler, Thomas, Pelzer, Theo, Wiewrodt, Rainer, Schütz, Martin, Serke, Monika, Stöhlmacher-Williams, Jan, Märten, Angela, Maria Huber, Rudolf, Dickgreber, Nicolas J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4276567/
https://www.ncbi.nlm.nih.gov/pubmed/25247337
http://dx.doi.org/10.1097/JTO.0000000000000380

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4276567/
https://www.ncbi.nlm.nih.gov/pubmed/25247337
http://dx.doi.org/10.1097/JTO.0000000000000380

Ejemplares similares